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Pancreatic cancer: 
define unresectable
Vivian McAlister
SWOSA 2009
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004200.
Palliative biliary stents for obstructing pancreatic 
carcinoma. (Moss AC, Morris E, Mac Mathuna P )
• 21 trials (1,454 patients) of endobiliary stent versus surgical 
bypass 
• 30 day mortality: RR 0.58, 95% CI 0.32, 1.04
• Complications: RR 0.60, 95% CI 0.45 - 0.81
• Recurrent biliary obstruction: RR 18.59, 95% CI 5.33 - 64.86
• Biliary obstruction -  metal versus plastic stent: RR 0.52, 95% CI 
0.39 - 0.69

• Resectable
• Curable
• Resection for cure
• Resection for improvement in length and 
quality of life
– Unresectable: the mortality/morbidity of resection 
is not substantially less than the gain in quantity 
and quality of life
Proceedings of the Consensus Conference 
(American Hepato-Pancreato-Biliary Association , 
Society for Surgery of the Alimentary Tract, the 
Society of Surgical Oncology, the Gastrointestinal 
Symposium Steering Committee, and the University 
of Texas M. D. Anderson Cancer Center)
Ann Surg Oncol (2009) 16:1727–1756
Pre-operative staging
• CT remains the diagnostic modality of choice but must 
be expertly performed
• CT poor at seeing pancreatic lesions < 2 cm, tiny liver 
lesions and peritoneal implants 
• CT prediction of unresectability: 90 – 100% accurate
• CT prediction of resectability: 70 – 90 % accurate
Definition of resectable; borderline and 
unresectable pancreatic carcinoma
• Unresectable if distant metastases, portal vein 
thrombosis (major) or circumferential 
encasement of celiac, hepatic or SMA
• Resectable if no metastases, no abutment or 
distortion of portal vein or SMV and clear fat 
planes around celiac, hepatic and superior 
mesenteric arteries
Pre-op evaluation: tissue
Biopsy of possible distant metastasis 
preferential to pancreas biopsy
Borderline resectable
Staging laparoscopy
Ferrone et al. J Gastrointestinal Surg 2006; 10: 1347-53
Ferrone et al. J Gastrointestinal Surg 2006; 10: 1347-53
Would extended lymphadenectomy increase resectiaility?
Would neoadjuvant therapy make 
borderline tumours resectable? 
MD Anderson borderline type
• Group A: Borderline anatomically
• Group B: Possible metastatic disease
• Group C: Resectable anatomically but in 
patients with marginal performance status
Katz et al JACS 2008; 206: 833-48


Neoadjuvant therapy for borderline resectable pancreatic cancer
Number of patients Median survival months
MD Anderson 
borderline type
All patients Resected Resected Not resected
Type A 84 32 40 15
Type B 44 22 29 12
Type C 32 12 39 13
All types 160 66 40 13
What is the best intra-operative strategy if 
R0/R1 resection not possible: palliative 
resection or bypass?
Median survival:
12 months vs. 9 months
Imamura et al. Surgery 2004; 136: 1003-11
Pancreatic cancer: define unresectable
• Biopsy proven metastases
– U.S. guided biopsy liver lesion
– E.U.S. guided biopsy lymph node
– Laparoscopic biopsy peritoneal lesion, omental 
lesion or distant metastasis
– Positive peritoneal lavage cytology
• Failure to complete neoadjuvant protocol with 
borderline resectable lesion (MD Anderson type B, 
C)
• Inability to complete R0/R1 resection
 
